De Novo Malignancies Screening After Liver Transplantation for Alcoholic Liver Disease: A Comparative Opportunistic Study. Issue 12 (4th December 2018)

• Record Type: Journal Article
• Authors: Renaud, Laurence; Hilleret, Marie‐Noëlle; Thimonier, Elsa; Guillaud, Olivier; Arbib, Francois; Ferretti, Gilbert; Jankowski, Adrien; Chambon‐Augoyard, Christine; Erard‐Poinsot, Domitille; Decaens, Thomas; Boillot, Olivier; Leroy, Vincent; Dumortier, Jérôme
• Is Part Of: Liver transplantation. Volume 24:Issue 12(2018)
• Page Start: 1690
• Page End: 1698
• Publication Date: 2018-12-04
• Subjects: Liver -- Transplantation -- Periodicals; Liver -- Diseases -- Periodicals; Liver Transplantation -- Periodicals; Foie -- Greffe -- Périodiques; 617.5560592
• DOI: 10.1002/lt.25336
• Languages: English
• ISSNs: 1527-6465

Abstract

Abstract : Patients having received a liver transplantation (LT) for alcoholic liver disease (ALD) have a high risk of de novo malignancies, especially in the upper aerodigestive tract and lungs due to their smoking and alcohol history. The aim of this retrospective study was to compare a group of patients transplanted for ALD who continue to smoke and who were included in an intensive screening program for tobacco‐related cancers implemented at the Grenoble University Hospital and a group of similar patients followed according to usual practice (chest computed tomography [CT] scan every 5 years) at the Edouard Herriot Hospital in Lyon. The intensive screening program consisted of an annual checkup, including a clinical examination by an otorhinolaryngologist, a chest CT scan, and an upper digestive endoscopy. A total of 147 patients were included: 71 patients in Grenoble and 76 patients in Lyon. The cumulative incidence of a first tobacco‐related cancer was 12.3% at 3 years, 20.6% at 5 years, 42.6% at 10 years, and 64.0% at 15 years. A curative treatment was possible in 80.0% of the patients in Grenoble versus 57.9% in Lyon ( P = 0.068). The rates of curative treatment were 63.6% versus 26.3% ( P = 0.062) for lung cancers, 100.0% versus 87.5% ( P = 0.498) for lip‐mouth‐pharynx and larynx cancers, and 66.7% versus 100.0% ( P = 1) for esophageal cancers, respectively. In addition, for lung cancers, regardless of study group, 68.7% received a curative treatment when the diagnosis was made by CT scan screening versus 14.3% when it was made because of symptoms ( P = 0.008). In conclusion, our study strongly confirms the high rate of tobacco‐related de novo malignancies in LT patients for ALD and suggests that the screening of lung cancer by annual chest CT scan could significantly increase the rate of curative treatment.